Definium Therapeutics
DFTX
84 hedge funds and large institutions have $13.9M invested in Definium Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 11 closing their positions.
905% more call options, than puts
Call options by funds: $9.99M | Put options by funds: $994K
11% more capital invested
Capital invested by funds: $12.6M → $13.9M (+$1.34M)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 10.36% → 10.08% (-0.28%)
5% less funds holding
Funds holding: 88 → 84 (-4)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$550K |
| 2 |
BlackRock
New York
|
+$350K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
+$195K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$173K |
| 5 |
Millennium Management
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$847K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$800K |
| 3 |
Renaissance Technologies
New York
|
-$66.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$51K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$39.3K |
DFTX Hedge Fund Activity: Q2 2023 in Review
84 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2023, worth a combined $13.9M — up 11% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DFTX and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was Cresset Asset Management, opening a new position worth an estimated $550K. The largest seller was Alyeska Investment Group, cutting an estimated $847K.
- 84 institutional investors held Definium Therapeutics (DFTX) as of Q2 2023, down from 88 in Q1 2023.
- Funds reported $13.9M of Definium Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
- 8 funds opened new Definium Therapeutics positions in Q2 2023 and 11 closed out, a net change of -3 holders.
- The largest Definium Therapeutics buyer in Q2 2023 was Cresset Asset Management, an estimated $550K added.
- The largest Definium Therapeutics seller in Q2 2023 was Alyeska Investment Group, an estimated $847K sold.
Based on aggregated 13F filings for Q2 2023.